MDMA After the FDA Rejection: A 1968 Pattern or a 2024 Delay?

The 2024 FDA rejection of MDMA-assisted therapy application is structurally different from the 1968 scheduling. In 1968: the research was producing positive results; scheduling was a political decision motivated by countercultural association; no scientific advisory committee recommended scheduling. In 2024: the FDA's Psychopharmacologic Drugs Advisory Committee voted 9-2 against approval on grounds of efficacy data quality and safety monitoring concerns, including unblinding (participants could tell if they received MDMA) and potential for therapist boundary violations. The concerns are genuine methodological problems, not political pretexts. The FDA requested an additional Phase 3 trial. The MAPS-affiliated sponsor is conducting it. The delay is real; the research is not stopped. The 1968 pattern was: research stopped by law. The 2024 pattern is: research slowed by methodology. Different in kind.